<DOC>
	<DOCNO>NCT02442284</DOCNO>
	<brief_summary>This study evaluate safety efficacy Ombitasvir/Paritaprevir/Ritonavir Dasabuvir without Ribavirin US veteran genotype 1 chronic hepatitis C virus infection .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Ombitasvir/Paritaprevir/Ritonavir Dasabuvir With Without Ribavirin US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . US military veteran currently receive healthcare Veterans Health Administration 2 . Screening laboratory result indicate HCV , genotype 1infection 3 . Positive hepatitis C antibodies HCV RNA least 6 month Screening , HCV RNA &gt; 1,000 IU/mL time Screening HCV RNA &gt; 1,000 IU/mL time Screening liver biopsy consistent chronic HCVinfection ( liver biopsy perform prior enrollment evidence chronic hepatitis C disease ) 1 . Women pregnant breastfeed 2 . Positive test result hepatitis B surface antigen ( HbsAg ) antiHIV antibody ( HIV Ab ) 3 . Prior current use investigational commercially available antiHCV agent IFN , pegIFN , RBV sofosbuvir 4 . Any current past clinical evidence ChildPugh B C classification 5 . Confirmed presence hepatocellular carcinoma indicate image technique within 3 month prior Screening ultrasound perform Screening participant cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>